Overview
GANX market data
Price History
GANX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GANX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Gain Therapeutics, Inc. (GANX)SEC EDGAR · Jul 16, 2026, 11:53 AM
Gain Therapeutics Appoints Terenzio Ignoni As COOBenzinga · Jul 16, 2026, 11:10 AM
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026Benzinga · Jul 16, 2026, 11:07 AM
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price TargetBenzinga · Jul 1, 2026, 11:55 AM
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26Benzinga · Jun 29, 2026, 8:15 PM
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitGlobenewswire Inc · Jun 10, 2026, 11:15 AM
Gain Therapeutics Q1 EPS $(0.13) Beats $(0.14) EstimateBenzinga · May 11, 2026, 11:19 AM